ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy
Despite remarkable advancements in cancer immunotherapy, its clinical efficacy remains constrained in solid tumors due to the immunosuppressive tumor microenvironment (TME). Reactive oxygen species (ROS), which exhibit dual regulatory roles in the TME by regulating immunogenic cell death (ICD) and r...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/7/886 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419043492069376 |
|---|---|
| author | Yuan-Yuan Fan Hong Wu Chuan Xu |
| author_facet | Yuan-Yuan Fan Hong Wu Chuan Xu |
| author_sort | Yuan-Yuan Fan |
| collection | DOAJ |
| description | Despite remarkable advancements in cancer immunotherapy, its clinical efficacy remains constrained in solid tumors due to the immunosuppressive tumor microenvironment (TME). Reactive oxygen species (ROS), which exhibit dual regulatory roles in the TME by regulating immunogenic cell death (ICD) and reprogramming immune cell functionality, have emerged as a pivotal therapeutic target. Nano-enabled drug delivery systems present distinct advantages for TME modulation due to their structural versatility, tumor-specific targeting precision, and spatiotemporally controlled drug release. In particular, ROS-responsive nanoplatforms demonstrate multifaceted immunomodulatory potential by synergistically restoring ICD and remodeling immunosuppressive immune cell phenotypes within the TME. These platforms further amplify the therapeutic outcomes of conventional modalities including chemotherapy, radiotherapy, and photodynamic therapy (PDT) through ROS-mediated sensitization mechanisms. This review comprehensively examines recent breakthroughs in ROS-responsive nanosystems for antitumor immunotherapy, emphasizing their mechanistic interplay with TME components and clinical translation potential. Herein, we provide a framework for developing integrated therapeutic strategies to overcome the current limitations in cancer immunotherapy. |
| format | Article |
| id | doaj-art-72785d1f3a384adf8a1990aa84bdc466 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-72785d1f3a384adf8a1990aa84bdc4662025-08-20T03:32:15ZengMDPI AGPharmaceutics1999-49232025-07-0117788610.3390/pharmaceutics17070886ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer ImmunotherapyYuan-Yuan Fan0Hong Wu1Chuan Xu2Chengdu University of Traditional Chinese Medicine, Chengdu 610072, ChinaDepartment of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, ChinaChengdu University of Traditional Chinese Medicine, Chengdu 610072, ChinaDespite remarkable advancements in cancer immunotherapy, its clinical efficacy remains constrained in solid tumors due to the immunosuppressive tumor microenvironment (TME). Reactive oxygen species (ROS), which exhibit dual regulatory roles in the TME by regulating immunogenic cell death (ICD) and reprogramming immune cell functionality, have emerged as a pivotal therapeutic target. Nano-enabled drug delivery systems present distinct advantages for TME modulation due to their structural versatility, tumor-specific targeting precision, and spatiotemporally controlled drug release. In particular, ROS-responsive nanoplatforms demonstrate multifaceted immunomodulatory potential by synergistically restoring ICD and remodeling immunosuppressive immune cell phenotypes within the TME. These platforms further amplify the therapeutic outcomes of conventional modalities including chemotherapy, radiotherapy, and photodynamic therapy (PDT) through ROS-mediated sensitization mechanisms. This review comprehensively examines recent breakthroughs in ROS-responsive nanosystems for antitumor immunotherapy, emphasizing their mechanistic interplay with TME components and clinical translation potential. Herein, we provide a framework for developing integrated therapeutic strategies to overcome the current limitations in cancer immunotherapy.https://www.mdpi.com/1999-4923/17/7/886reactive oxygen speciesROS-responsive drug deliverytumor microenvironmentimmunogenic cell deathantitumor therapy |
| spellingShingle | Yuan-Yuan Fan Hong Wu Chuan Xu ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy Pharmaceutics reactive oxygen species ROS-responsive drug delivery tumor microenvironment immunogenic cell death antitumor therapy |
| title | ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy |
| title_full | ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy |
| title_fullStr | ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy |
| title_full_unstemmed | ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy |
| title_short | ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy |
| title_sort | ros responsive nanoplatforms for targeted tumor immunomodulation a paradigm shift in precision cancer immunotherapy |
| topic | reactive oxygen species ROS-responsive drug delivery tumor microenvironment immunogenic cell death antitumor therapy |
| url | https://www.mdpi.com/1999-4923/17/7/886 |
| work_keys_str_mv | AT yuanyuanfan rosresponsivenanoplatformsfortargetedtumorimmunomodulationaparadigmshiftinprecisioncancerimmunotherapy AT hongwu rosresponsivenanoplatformsfortargetedtumorimmunomodulationaparadigmshiftinprecisioncancerimmunotherapy AT chuanxu rosresponsivenanoplatformsfortargetedtumorimmunomodulationaparadigmshiftinprecisioncancerimmunotherapy |